Skip to main content
. 2020 Mar 18;10(3):e034716. doi: 10.1136/bmjopen-2019-034716

Figure 3.

Figure 3

Base case incremental costs (vs No Testing) and the proportion of monogenic diabetes cases identified for each strategy.